A 43-year-old woman presented with 6 months of recurrent bilateral eye pain and redness alongside spontaneous urticaria.She ...

Explore holistic approaches to treating the atopic triad in children—eczema, asthma, and allergies—with naturopathic ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology.

Slides coated with C. luciliae were incubated with diluted sera. In case of a positive sample, specific IgG, IgA, and IgM antibodies bind to the flagellate antigen. During the second incubation step, ...

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody isotopes for cancer.

The acquisition not only gives Epsilogen the capability of selecting the appropriate antibody isotype for a given cancer, given the differentiated therapeutic mechanisms of each, but also allows it to ...

Looking ahead, Epsilogen sees the deal as giving it the option to “mix and match IgE, IgA and IgG functionality into a single antibody molecule.” “Such hybrid antibodies have the potential ...